Genetically modified mice that were born with no calcium ion channels that was resulting in secondary brain damage and the results showed exactly what the stroke pre clinical study proved up, when these channels were inhibited with the drug it stop secondary brain injury
The stock went down because of negativity of the cholesterol lowering drug with a potential market size of 900 million dollars. The current drug for stroke and traumatic brain injury is a 55 billion dollar target market. It’s going to run either way come Walter reed results and GLP study results next month because it’s not a 6 million dollar EV drug
Genetically modified mice that were born with no calcium ion...
Add NYR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.0¢ |
Change
0.002(2.94%) |
Mkt cap ! $12.55M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.0¢ | 6.9¢ | $2.941K | 42.27K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 29850 | 6.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.0¢ | 152870 | 2 |
View Market Depth
| Last trade - 16.10pm 21/05/2024 (20 minute delay) ? |
|
|||||
|
Last
6.9¢ |
Change
0.002 ( 2.99 %) |
||||
| Open | High | Low | Volume | ||
| 6.8¢ | 6.9¢ | 6.7¢ | 101370 | ||
| Last updated 16.10pm 21/05/2024 ? | |||||
| NYR (ASX) Chart |